Transition From Pde-5 Inhibitors To Riociguat In Pulmonary Hypertension

被引：0
|
作者：
Weir, N. [1 ]
Brown, A. W. [2 ]
DelaSantina, J. [2 ]
King, C. [2 ]
Lewis, D. [1 ]
Franco-Palacios, D. [2 ]
Nathan, S. D. [1 ]
Shlobin, O. A. [2 ]
机构：
[1] Inova Fairfax Hosp, Falls Church, VA USA
[2] Inova Fairfax Hosp, Kensington, MD USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2017年 / 195卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2282
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PDE-5 Inhibitors for BPH-Associated LUTS
    Brousil, Philip
    Shabbir, Majid
    Zacharakis, E.
    Sahai, Arun
    CURRENT DRUG TARGETS, 2015, 16 (11) : 1180 - 1186
  • [32] PENILE PROSTHETIC SURGERY IN THE ERA OF PDE-5 INHIBITORS
    ZChoi, Hyung Ki
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 : 145 - 145
  • [33] Short term effect of Selexipag in pulmonary arterial hypertension patients started on double combination therapy with ERA and PDE-5 inhibitors
    Guarino, Daniele
    Dardi, Fabio
    Palazzini, Massimiliano
    Rinaldi, Andrea
    Zuffa, Elisa
    Pasca, Filippo
    De Lorenzis, Alessandro
    Magnani, Ilenia
    Rotunno, Mariangela
    Ballerini, Alberto
    Manes, Alessandra
    Galie, Nazzareno
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0J) : J80 - J80
  • [34] Changes in cMRI parameters following a switch to riociguat from phosphodiesterase type 5 inhibitors (PDE5i) in patients with pulmonary arterial hypertension: a REPLACE substudy
    Rosenkranz, S.
    Benza, R. L.
    Ghofrani, H. A.
    Gruenig, E.
    Hoeper, M. M.
    Peacock, A.
    Simonneau, G.
    Vizza, D.
    Meier, C.
    Vogtlaender, K.
    Vonk-Noordegraaf, A.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1966 - 1966
  • [35] Effect of Phosphodiesterase-5 (PDE-5) Inhibitors on Clinical Outcomes in Patients With Pulmonary Hypertension: A Meta-Analysis of Randomized Control Trials
    Karedath, Jithin
    Dar, Hassaan
    Ganipineni, Vijay Durga Pradeep
    Gorle, Sri Anjali
    Gaddipati, Sarvani
    Bseiso, Anan
    Pizzorno, Guiomarly
    Shaik, Tanveer Ahamad
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
  • [36] PDE-5 inhibitor treatment may give patients with severe pulmonary hypertension a survival benefit
    不详
    RESPIROLOGY, 2015, 20 (05) : 849 - 849
  • [37] Phosphodiesterase-5 (PDE-5) Inhibitors and Ototoxicity: A Systematic Review
    Manna, Sayan
    Gray, Mingyang Liu
    Kaul, Vivian F.
    Wanna, George
    OTOLOGY & NEUROTOLOGY, 2019, 40 (03) : 276 - 283
  • [38] A Case of Chronic Heart Failure with Severe Pulmonary Hypertension Successfully Treated with PDE-5 Inhibitor
    Takakura, Midori
    Kato, Shingo
    Azuma, Mai
    Iinuma, Naoki
    Kusakawa, Yuka
    Shimizu, Satoru
    Miki, Yuko
    Nakachi, Tatsuya
    Fukui, Kazuki
    JOURNAL OF CARDIAC FAILURE, 2016, 22 (09) : S193 - S194
  • [39] Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study
    Kuroda, Kazuhiro
    Akagi, Satoshi
    Nakamura, Kazufumi
    Sarashina, Toshihiro
    Ejiri, Kentaro
    Ito, Hiroshi
    HEART LUNG AND CIRCULATION, 2020, 29 (03): : 331 - 336
  • [40] Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: A case report
    Jochmann N.
    Kiecker F.
    Borges A.C.
    Hofmann M.A.
    Eddicks S.
    Sterry W.
    Baumann G.
    Trefzer U.
    Cardiovascular Ultrasound, 3 (1)
12345